At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
Candida albicans Skin Test Antigenbiological
Likely dose
Candida albicans Skin Test Antigen 0.3 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of the Safety and Effectiveness of Candin for the Treatment of Common Warts
In Brief
A Phase 2 clinical trial evaluating Candida albicans Skin Test Antigen for Warts and Human Papilloma Virus. Completed, enrolled 39 participants across 1 site.
Detailed Summary
The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at a 0.3 ml dose level at up to 6 monthly injections for treating common warts (Verruca vulgaris).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWarts, Human Papilloma Virus
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2012
First PostedDec 2012
Primary CompletionDec 2014
TodayJul 2026
First PostedDec 28, 2012
Enrollment StartSep 1, 2012
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.5 years ago
Interventions
Candida albicans Skin Test Antigenbiological
0.3 ml injected intralesionally monthly. Number of injections: until wart lesion is resolved or up to 6 injections.